BR112019003957A2 - proteína de ligação a fator h modificado - Google Patents

proteína de ligação a fator h modificado

Info

Publication number
BR112019003957A2
BR112019003957A2 BR112019003957A BR112019003957A BR112019003957A2 BR 112019003957 A2 BR112019003957 A2 BR 112019003957A2 BR 112019003957 A BR112019003957 A BR 112019003957A BR 112019003957 A BR112019003957 A BR 112019003957A BR 112019003957 A2 BR112019003957 A2 BR 112019003957A2
Authority
BR
Brazil
Prior art keywords
modified
binding protein
factor binding
fhbp
relates
Prior art date
Application number
BR112019003957A
Other languages
English (en)
Portuguese (pt)
Inventor
M Tang Christoph
Original Assignee
Univ Oxford Innovation Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Oxford Innovation Ltd filed Critical Univ Oxford Innovation Ltd
Publication of BR112019003957A2 publication Critical patent/BR112019003957A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/22—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Neisseriaceae (F)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/095—Neisseria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6068—Other bacterial proteins, e.g. OMP
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
BR112019003957A 2016-08-31 2017-08-31 proteína de ligação a fator h modificado BR112019003957A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1614687.0A GB201614687D0 (en) 2016-08-31 2016-08-31 fHbp scaffold
PCT/GB2017/052535 WO2018042178A1 (en) 2016-08-31 2017-08-31 Modified factor h binding protein

Publications (1)

Publication Number Publication Date
BR112019003957A2 true BR112019003957A2 (pt) 2019-06-25

Family

ID=57119942

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112019003957A BR112019003957A2 (pt) 2016-08-31 2017-08-31 proteína de ligação a fator h modificado

Country Status (13)

Country Link
US (1) US12497432B2 (enExample)
EP (1) EP3506934A1 (enExample)
JP (1) JP7525093B2 (enExample)
KR (1) KR102643280B1 (enExample)
CN (1) CN109890412B (enExample)
AU (1) AU2017319218B2 (enExample)
BR (1) BR112019003957A2 (enExample)
CA (1) CA3035159A1 (enExample)
GB (2) GB201614687D0 (enExample)
IL (1) IL265078B2 (enExample)
MX (1) MX420767B (enExample)
WO (1) WO2018042178A1 (enExample)
ZA (1) ZA201901862B (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201614687D0 (en) * 2016-08-31 2016-10-12 Univ Oxford Innovation Ltd fHbp scaffold
CN110903400A (zh) * 2019-11-08 2020-03-24 苏州微超生物科技有限公司 B群脑膜炎球菌fHBP多变体融合蛋白及其制备方法与应用
CN111533792B (zh) * 2020-07-07 2020-10-16 康希诺生物股份公司 一种定点突变的载体蛋白及其在制备疫苗中的用途
JPWO2022071291A1 (enExample) * 2020-09-29 2022-04-07
IN202321021121A (enExample) * 2023-03-24 2024-04-19

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX339524B (es) * 2001-10-11 2016-05-30 Wyeth Corp Composiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedad meningococica.
US7351413B2 (en) * 2002-02-21 2008-04-01 Lorantis, Limited Stabilized HBc chimer particles as immunogens for chronic hepatitis
US7785608B2 (en) * 2002-08-30 2010-08-31 Wyeth Holdings Corporation Immunogenic compositions for the prevention and treatment of meningococcal disease
HUE047780T2 (hu) * 2002-10-11 2020-05-28 Glaxosmithkline Biologicals Sa Polipeptid vakcinák hipervirulens meningokokkusz vonalak elleni széles-spektrumú védelemre
GB0227346D0 (en) * 2002-11-22 2002-12-31 Chiron Spa 741
AU2003300841B2 (en) * 2002-12-10 2008-03-20 Lorantis Ltd. Stabilized immunogenic HBc chimer particles
ES2411080T3 (es) * 2003-01-30 2013-07-04 Novartis Ag Vacunas inyectables contra múltiples serogrupos de meningococos
EP1961426B1 (en) * 2003-10-02 2011-04-27 Novartis Vaccines and Diagnostics S.r.l. Combined meningitis vaccines
GB0408977D0 (en) * 2004-04-22 2004-05-26 Chiron Srl Immunising against meningococcal serogroup Y using proteins
GB2414667A (en) * 2004-06-03 2005-12-07 Isis Innovation Vaccine compositions of N. meningitidis PorA and FetA antigens
WO2006011060A2 (en) * 2004-07-23 2006-02-02 Chiron Srl Polypeptides for oligomeric assembly of antigens
GB0419408D0 (en) * 2004-09-01 2004-10-06 Chiron Srl 741 chimeric polypeptides
JP4993750B2 (ja) * 2005-01-27 2012-08-08 チルドレンズ ホスピタル アンド リサーチ センター アット オークランド 髄膜炎菌に起因する疾患に対する広域防御のための、ｇｎａ１８７０を基にした小胞ワクチン
GB0524066D0 (en) * 2005-11-25 2006-01-04 Chiron Srl 741 ii
EP1925318A1 (en) * 2006-11-20 2008-05-28 Paul-Ehrlich-Institut Recombinant modified vaccinia virus Ankara (MVA)-based vaccine for the avian flu
RU2475496C2 (ru) * 2008-02-21 2013-02-20 Новартис Аг МЕНИНГОКОККОВЫЕ ПОЛИПЕПТИДЫ fHBP
CA2717870A1 (en) * 2008-03-10 2009-09-17 Children's Hospital & Research Center At Oakland Chimeric factor h binding proteins (fhbp) containing a heterologous b domain and methods of use
AU2009262893B2 (en) * 2008-05-30 2015-05-21 The U.S.A., as represented by The Secretary of the Army, on behalf of Walter Reed Army Institute Of Research Meningococcal multivalent native outer membrane vesicle vaccine, methods of making and use thereof
CA2726512A1 (en) * 2008-06-09 2009-12-17 Novartis Ag Antibodies against neisserial factor h binding protein
CA2733943A1 (en) * 2008-09-03 2010-03-11 Children's Hospital & Research Center At Oakland Peptides presenting an epitope of an a domain of factor h binding protein and methods of use
GB0819633D0 (en) * 2008-10-25 2008-12-03 Isis Innovation Composition
CA2756522C (en) * 2009-03-24 2018-06-26 Novartis Ag Adjuvanting meningococcal factor h binding protein
AU2010242905B2 (en) * 2009-04-30 2014-10-23 Children's Hospital & Research Center At Oakland Chimeric factor H binding proteins (fHbp) and methods of use
BR112012004275A2 (pt) * 2009-08-27 2016-11-16 Novartis Ag polipeptídios híbridos incluindo sequências meningocócicas de fhbp
CA2779816A1 (en) * 2009-10-27 2011-05-05 Novartis Ag Modified meningococcal fhbp polypeptides
BR112012022669A2 (pt) * 2010-03-10 2017-02-14 Glaxosmithkline Biologicals Sa composição imunogênica, método de tratamento ou prevenção de infecção ou doença, uso de um antígeno, kit, métodos para a fabricação de uma composição imunogênica e para melhorar uma vacina.
TR201802933T4 (tr) * 2010-03-30 2018-03-21 Childrens Hospital & Res Center At Oakland Özellikleri değiştirilmiş faktör h bağlama proteinleri (fhbp) ve bunların kullanım yöntemi.
EP2556085A2 (en) * 2010-04-05 2013-02-13 Bar-Ilan University Protease-activatable pore-forming polypeptides
US10478483B2 (en) * 2010-06-25 2019-11-19 Glaxosmithkline Biologicals Sa Combinations of meningococcal factor H binding proteins
GB201015132D0 (en) 2010-09-10 2010-10-27 Univ Bristol Vaccine composition
NZ607224A (en) * 2010-09-10 2014-11-28 Wyeth Llc Non-lipidated variants of neisseria meningitidis orf2086 antigens
WO2013078223A1 (en) * 2011-11-23 2013-05-30 Children's Hospital & Research Center Oakland Anti-factor h binding protein antibodies and methods of use thereof
AU2011384634A1 (en) * 2011-12-29 2014-06-19 Novartis Ag Adjuvanted combinations of meningococcal factor H binding proteins
EP2823312B1 (en) * 2012-03-08 2019-08-07 GlaxoSmithKline Biologicals SA In vitro potency assay for protein-based meningococcal vaccines
SA115360586B1 (ar) * 2012-03-09 2017-04-12 فايزر انك تركيبات لعلاج الالتهاب السحائي البكتيري وطرق لتحضيرها
RU2665841C2 (ru) * 2012-03-09 2018-09-04 Пфайзер Инк. Композиции neisseria meningitidis и способы их применения
EP2861247B1 (en) * 2012-06-14 2020-12-09 GlaxoSmithKline Biologicals SA Vaccines for serogroup x meningococcus
GB201215005D0 (en) * 2012-08-23 2012-10-10 Isis Innovation Stabilised meningitis vaccine
EP2964665B1 (en) * 2013-03-08 2018-08-01 Pfizer Inc Immunogenic fusion polypeptides
WO2014140562A1 (en) * 2013-03-14 2014-09-18 Isis Innovation Limited Immunogenic composition to neisseria
BR112016004463A2 (pt) * 2013-09-08 2017-10-17 Pfizer composições de neisseria meningitidis e métodos das mesmas
SG10201907875TA (en) * 2014-02-28 2019-09-27 Glaxosmithkline Biologicals Sa Modified meningococcal fhbp polypeptides
WO2016014719A1 (en) * 2014-07-23 2016-01-28 Children's Hospital & Research Center Oakland Factor h binding protein variants and methods of use thereof
AU2015352404A1 (en) 2014-11-28 2017-05-18 Janssen Vaccines & Prevention B.V. Meningitis B vaccine
US10888611B2 (en) * 2015-02-19 2021-01-12 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
GB201614687D0 (en) * 2016-08-31 2016-10-12 Univ Oxford Innovation Ltd fHbp scaffold
CN118021947A (zh) * 2017-01-31 2024-05-14 辉瑞大药厂 脑膜炎奈瑟菌组合物及其使用方法

Also Published As

Publication number Publication date
NZ751995A (en) 2024-03-22
ZA201901862B (en) 2020-09-30
CN109890412A (zh) 2019-06-14
EP3506934A1 (en) 2019-07-10
IL265078A (enExample) 2019-04-30
IL265078B1 (en) 2023-04-01
WO2018042178A1 (en) 2018-03-08
US12497432B2 (en) 2025-12-16
KR102643280B1 (ko) 2024-03-05
AU2017319218B2 (en) 2021-10-28
US20220112249A1 (en) 2022-04-14
MX420767B (es) 2025-02-10
MX2019002248A (es) 2019-09-18
CN109890412B (zh) 2025-04-04
AU2017319218A2 (en) 2019-05-02
GB201614687D0 (en) 2016-10-12
GB2568440A (en) 2019-05-15
JP7525093B2 (ja) 2024-07-30
IL265078B2 (en) 2023-08-01
GB201903866D0 (en) 2019-05-08
AU2017319218A1 (en) 2019-04-18
CA3035159A1 (en) 2018-03-08
JP2019526261A (ja) 2019-09-19
KR20190064577A (ko) 2019-06-10
GB2568440B (en) 2022-08-17

Similar Documents

Publication Publication Date Title
BR112019003957A2 (pt) proteína de ligação a fator h modificado
PH12020550051A1 (en) Glp-1 compositions and uses thereof
BR112018073761A2 (pt) proteínas de ligação ao cd3 de fragmento variável de cadeia única
EA201892489A1 (ru) Число мишеней для мультиплексной оптимизированной амплификации с несоответствиями (moma)
BR112018010805A2 (pt) mutantes de proteína f de rsv
BR112018076190A2 (pt) ortólogos e sistemas crispr tipo vi
AU2016240220B2 (en) Designed ankyrin repeat domains with binding specificity for serum albumin
EP4477662A3 (en) Nucleic acid molecules and uses thereof
EA201692309A1 (ru) Стереохимически обогащенные композиции для доставки нуклеиновых кислот
EA201891201A1 (ru) Композиции, содержащие бактериальные штаммы
BR112018005928A2 (pt) composição ácida compreendendo uma ficocianina
EA201890050A1 (ru) Композиции, содержащие бактериальные штаммы
EA201890049A1 (ru) Композиции, содержащие бактериальные штаммы
BR112018007572A2 (pt) composições fungicidas
EA201891399A1 (ru) Бипиразолильные производные, пригодные для лечения аутоиммунных заболеваний
SG10201908839QA (en) 2,4-dihydroxy-nicotinamides as apj agonists
BR112017001417A2 (pt) variantes de proteína de ligação ao fator h e métodos para uso das mesmas
WO2017053732A3 (en) Composition and method for treating complement-mediated disease
MX385972B (es) Partículas y composiciones de nicotina.
WO2018226992A8 (en) Tau aggregation inhibitors
BR112016026842A2 (pt) preparação compreendendo fator viii e peptídeos de fator de von willebrand
EP4574207A3 (en) Means and methods for treating copper-related diseases
MX2017008567A (es) Dnasa modificada y usos de la misma.
BR112018017247A2 (pt) ?polinucleotídeo, vetor de ácido nucleico, preparação farmacêutica, kit, e, métodos para fabricar um vetor viral adenoassociado recombinante e para tratar uma doença?
MX390418B (es) Anticuerpos anti proteína similar a angiopoyetina 4 y métodos de uso.

Legal Events

Date Code Title Description
B350 Update of information on the portal [chapter 15.35 patent gazette]
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]